Two-year outcomes of intravitreal conbercept therapy for polypoidal choroidal vasculopathy [PDF]
BMC OphthalmologyBackground This study aims to evaluate the two-year outcomes of polypoidal choroidal vasculopathy (PCV) treated with conbercept and to investigate the predictive response factors.
Yang Liu +4 more
doaj +4 more sources
Anti-scarring effects of conbercept on human Tenon’s fibroblasts: comparisons with bevacizumab
BMC Ophthalmology, 2023 Background Safely inhibiting the formation of scar in the glaucoma filtration surgery (GFS) has always been an issue for clinical glaucoma doctors. Anti-vascular endothelial growth factor (VEGF) agents can reduce angiogenesis, and anti-placental growth ...
Lei Zuo +3 more
doaj +3 more sources
Intravitreal conbercept injection for neovascular age-related macular degeneration [PDF]
International Journal of Ophthalmology, 2019 AIM: To evaluate the efficacy and safety of intravitreal injection of conbercept in patients with neovascular age-related macular degeneration (AMD). METHODS: Retrospective review of 66 eyes of 63 patients with neovascular AMD. All patients received 0.5
Bing-Hui Wu +4 more
doaj +3 more sources
Effect and factors associated with reactivation after intravitreal conbercept or aflibercept in retinopathy of prematurity [PDF]
European Journal of Medical ResearchBackground To evaluate the effect and factors associated with the reactivation of retinopathy of prematurity (ROP) after intravitreal conbercept or aflibercept.
Chunling Huang +10 more
doaj +2 more sources
Recent advances in the study of Conbercept for diabetic macular edema [PDF]
International Journal of Retina and VitreousDiabetic macular edema (DME) is one of the leading causes of blindness in diabetic retinopathy. As a domestically developed fusion protein drug in China, the anti-vascular endothelial growth factor (VEGF) agent Conbercept has demonstrated significant ...
Zhe Liu, Xin Zheng, Hong Li
doaj +2 more sources
The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review [PDF]
Journal of Ophthalmology, 2020 Topic. The aim of this study is to evaluate the efficacy of conbercept in PCV, which will optimize the management for PCV patients. Clinical Relevance. The use of antivascular endothelial growth factor (VEGF) therapy in polypoidal choroidal vasculopathy (
Yimin Wang +4 more
doaj +3 more sources
Comparative study on the efficacy of Conbercept and Aflibercept in the treatment of neovascular age-related macular degeneration [PDF]
Scientific ReportsThis study compares the effectiveness of Conbercept and Aflibercept in treating neovascular age-related macular degeneration (nAMD). Conducted at the First Affiliated Hospital of Chongqing Medical University's Ophthalmology Department (May 2020–May 2023),
Hao Xie +4 more
doaj +2 more sources
Intravitreal ranibizumab or conbercept for retinal arterial macroaneurysm: a case series [PDF]
BMC Ophthalmology, 2019 Background There is no consensus for the standard treatment of retinal arterial macroaneurysm (RAM). Intravitreal anti-vascular endothelium growth factor (anti-VEGF) is an alternative treatment option for RAM. The purpose of this study is to describe the
Zhongjing Lin +4 more
doaj +3 more sources
Subconjunctival conbercept for the treatment of corneal neovascularization
International Journal of Ophthalmology, 2023 AIM: To investigate the effectiveness and safety of subconjunctival injection of conbercept in the treatment of corneal neovascularization (CNV). METHODS: The data on 10 consecutively recruited patients with CNV who received a subconjunctival conbercept (1 mg) once, and measured the area, length, and diameter of neovascularization before and after (1d,
Cun Sun +3 more
openalex +5 more sources